ARTICLE | Company News
China approves Descovy, Harvoni, Hemlibra
December 4, 2018 8:34 PM UTC
China's National Medical Products Administration (NMPA) has issued new approvals for three drugs marketed in the U.S. and EU: Descovy emtricitabine/tenofovir alafenamide and Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), and Hemlibra emicizumab-kxwh from Roche (SIX:ROG; OTCQX:RHHBY).
Hemlibra's Chinese approval to treat hemophilia A comes a little over a year after FDA approved the drug in the same indication. The EU also approved Hemlibra in the indication in February (see "EC Approves Roche's Hemlibra for Hemophilia A"). ...